Bank of America Corp DE reduced its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 82.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,712 shares of the biotechnology company's stock after selling 130,775 shares during the quarter. Bank of America Corp DE owned 0.10% of Arcturus Therapeutics worth $470,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Virtus ETF Advisers LLC raised its holdings in Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after acquiring an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Arcturus Therapeutics in the 4th quarter valued at about $71,000. National Bank of Canada FI raised its holdings in Arcturus Therapeutics by 639.6% in the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 4,784 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in Arcturus Therapeutics by 22.7% in the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company's stock valued at $186,000 after acquiring an additional 2,036 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Arcturus Therapeutics by 52.7% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 13,461 shares of the biotechnology company's stock worth $241,000 after buying an additional 4,647 shares during the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on ARCT. Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Canaccord Genuity Group cut their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Wall Street Zen upgraded shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Scotiabank initiated coverage on shares of Arcturus Therapeutics in a report on Wednesday, May 28th. They set a "sector outperform" rating and a $32.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $53.50.
View Our Latest Stock Report on ARCT
Arcturus Therapeutics Price Performance
Shares of Arcturus Therapeutics stock traded down $0.26 during trading on Friday, hitting $12.38. 433,067 shares of the stock were exchanged, compared to its average volume of 438,242. The stock has a market cap of $335.76 million, a price-to-earnings ratio of -5.58 and a beta of 2.30. The firm's 50-day moving average price is $11.69 and its 200 day moving average price is $14.48. Arcturus Therapeutics Holdings Inc. has a 12-month low of $8.04 and a 12-month high of $31.59.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $1.06. The business had revenue of $29.38 million during the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.
About Arcturus Therapeutics
(
Free Report)
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Recommended Stories
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
